Loading…

Knockdown of ANO1 decreases TGF-β- and IL-6-induced adhesion and migration of cardiac fibroblasts by inhibiting the expression of integrin and focal adhesion kinase

Ischemic cardiac injury triggers a significant inflammatory response, activating and mobilizing cardiac fibroblasts (CFs), which ultimately contributes to myocardial fibrosis. In this study, we investigated the role of ANO1, a calcium-activated chloride channel (CaCC) protein, in regulating CFs migr...

Full description

Saved in:
Bibliographic Details
Published in:Experimental cell research 2024-11, Vol.443 (1), p.114321, Article 114321
Main Authors: Tian, Xiangqin, Zhang, Yajing, Gong, Hezhe, Bai, Mengru, Sun, Changye, Jia, Yangyang, Duan, Changen, Wang, Xianwei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ischemic cardiac injury triggers a significant inflammatory response, activating and mobilizing cardiac fibroblasts (CFs), which ultimately contributes to myocardial fibrosis. In this study, we investigated the role of ANO1, a calcium-activated chloride channel (CaCC) protein, in regulating CFs migration and adhesion under inflammatory conditions. Our results demonstrated that ANO1 knockdown significantly attenuated TGF-β- and IL-6-induced adhesion and migration of CFs. This inhibitory effect was mediated through the downregulation of integrin expression and reduced activation of focal adhesion kinase (FAK), key components in cellular adhesion and motility pathways. This study provides new insights into the mechanisms underlying CFs migration and adhesion, highlighting the potential of ANO1 as a therapeutic target for mitigating adverse fibrotic remodeling following myocardial infarction. [Display omitted] •Inhibition of ANO1 significantly reduces CFs migration and adhesion.•ANO1 affects CFs migration and adhesion by regulating the expression of integrins and focal adhesion kinase.•The study indicates that ANO1 has potential as a therapeutic target for mitigating adverse fibrotic remodeling post-myocardial infarction.
ISSN:0014-4827
1090-2422
1090-2422
DOI:10.1016/j.yexcr.2024.114321